Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality
Metadatos
Mostrar el registro completo del ítemAutor
Nakanishi, Tomoko; Martínez Bueno, Manuel; García García, Federico; Alarcón Riquelme, Marta Eugenia; FinnGen; The COVID-19 Host Genetics InitiativeEditorial
American Society for Clinical Investigation
Fecha
2021-03-12Referencia bibliográfica
Published version: Nakanishi, T... [et al.]. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. J Clin Invest. 2021;131(23):e152386. [https://doi.org/10.1172/JCI152386]
Patrocinador
Academy of Finland Fellow grant N. 323116; Academy of Finland for PREDICT consortium N. 340541.; Canadian Institutes of Health Research (CIHR) (365825 and 409511); Lady Davis Institute of the Jewish General Hospital; Canadian Foundation for Innovation (CFI); NIH Foundation; Cancer Research UK; Genome Québec; Public Health Agency of Canada; McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Québec Santé (FRQS); Japan Society for the Promotion of Science for Young Scientists; CIHR scholarship and a joint FRQS and Québec Ministry of Health and Social Services scholarship; FRQS Clinical Research Scholarship; Calcul Québec; Compute Canada; Welcome Trust; Medical Research Counc; European Union; National Institute for Health Research-funded BioResource; Clinical Research Facility and Biomedical Research Centre based at Guy’s and St. Thomas’ NHS Foundation Trust; King’s College London; Genome Québec; Public Health Agency of Canada; McGill Interdisciplinary Initiative in Infection and Immunity; Fonds de Recherche Québec Santé; (DFG Grant: “EXC2167”); (CompLS grant 031L0165); Stein Erik Hagen; "Grupo de Trabajo en Medicina Personalizada contra el COVID-19 de Andalucia"; Instituto de Salud Carlos III (CIBERehd and CIBERER); COVID-19-GWAS; COVID-PREMED initiatives; "Consejeria de Salud y Familias" of the Andalusian Government; Andalusian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018); Columbia University; National Center for Advancing Translational Sciences; NIH Grant Number UL1TR001873; Consejería de Economía, Conocimiento, Empresas y Universidad #CV20-10150; MIUR grant “Dipartimenti di Eccellenza 2018-2020”; “Intesa San Paolo 2020 charity fund” dedicated to the project NB/2020/0119; Tuscany Region “Bando Ricerca COVID-19 Toscana”; CINECA consortium; Network for Italian Genomes (NIG); COVID-19 Host Genetics Initiative; Genetic Biobank of Siena; EuroBioBank; RD-Connect; Ricerca Corrente (Italian Ministry of Health); Fondazione Humanitas per la Ricerca; Banca Intesa San Paolo; Dolce&Gabbana Fashion Firm; COVID-19 Biobank; Fondazione IRCCS Cà Granda Milano; MyFirst Grant AIRC n.16888; Ricerca Finalizzata Ministero della Salute RF-2016-02364358; Ricerca corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377); “Photonics” “101016726”; Fondazione Patrimonio Ca’ Granda “Liver Bible” PR-0361; CV PREVITAL “Strategie di prevenzione primaria nella popolazione Italiana” Ministero della Salute, and Associazione Italiana per la Prevenzione dell’Epatite Virale (COPEV); "Fonds Erasme"; Fondation Léon Fredericq; Fonds de la Recherche Scientifique (FNRS); Consejo Superior de Investigaciones Científicas; German Research Foundation (LU 1944/3-1); SciLifeLab/KAW national COVID-19 research program project (KAW 2020.0182); Swedish Research Council (2014-02569 and 2014-07606); Jeansson Stiftelser, Magnus Bergvalls Stiftelse; Technical University of Munich, Munich, Germany; Genotyping Laboratory of Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki, Helsinki, FinlandResumen
Background: There is considerable variability in COVID-19 outcomes amongst younger
adults—and some of this variation may be due to genetic predisposition. We characterized the
clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent
effect, using individual-level data in a large international multi-centre consortium.
Method: The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by
the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive
patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this
genetic marker with mortality, COVID-19-related complications and laboratory values. We next
examined if the magnitude of these associations varied by age and were independent from
known clinical COVID-19 risk factors.
Findings: We found that rs10490770 risk allele carriers experienced an increased risk of
all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2–1·6) and COVID-19
related mortality (HR 1·5, 95%CI 1·3–1·8). Risk allele carriers had increased odds of several
COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6),
venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI
1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure
(OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction
p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory
COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers,
compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes.
Prediction of death or severe respiratory failure among those ≤ 60 years improved when
including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770
risk allele was similar to, or better than, most established clinical risk factors.
Interpretation: The major common COVID-19 risk locus on chromosome 3 is associated with
increased risks of morbidity and mortality—and these are more pronounced amongst individuals
≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk
factors, suggesting potential implications for clinical risk management.